[The effects of phenylbutazone on the decrease of lithium clearance].
During the treatment of a manic depressive patient, the authors reported some lithium toxicity signs, as lithium carbonate (3 X 300 mg p.d.) and phenylbutazone suppository (3 X 250 mg/p.d.) were associated, this last medication being prescribed for a phlebitis. Lithiemia increased from .70 to 1,44 mEq/l., the lithiemia clearance falling from 10 ml to 5 ml/mn/1.73 m2) and the lithium tubular reabsorption percentage increasing from 85 to 94% (standard rates: 77.4 +/- 1.3%). In a second time, a rat experimentation corroborated these findings: phenylbutazone treatment (100 mg/kg/p.o. for five days) resulted in a lithium tubular reabsorption increase. It seems that the association of lithium carbonate with phenylbutazone should be avoided. The authors point out the risk of prescribing lithium and pyrazolic by-products as phenylbutazone, which are potentially nephrotoxic.
D000818:Animals; D001714:Bipolar Disorder / Q000188:drug therapy*; D004347:Drug Interactions; D006801:Humans; D007668:Kidney / Q000187:drug effects; D007686:Kidney Tubules, Distal / Q000503:physiopathology; D008094:Lithium / Q000009:adverse effects* / Q000652:urine; D008297:Male; D010653:Phenylbutazone / Q000009:adverse effects*; D010689:Phlebitis / Q000188:drug therapy; D051381:Rats
D008094:Lithium; D010653:Phenylbutazone
Baisse de la clearance rénale du lithium sous l'effet de la phénylbutazone.